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Extracting relevant information from large-scale data
offers unprecedented opportunities in cancerology.
We applied independent component analysis (ICA)
to bladder cancer transcriptome data sets and inter-
preted the components using gene enrichment anal-
ysis and tumor-associated molecular, clinicopatho-
logical, and processing information. We identified
components associated with biological proces-
ses of tumor cells or the tumor microenvironment,
and other components revealed technical biases.
Applying ICA to nine cancer types identified cancer-
shared and bladder-cancer-specific components.
We characterized the luminal and basal-like subtypes
of muscle-invasive bladder cancers according to the
components identified. The study of the urothelial
differentiation component, specific to the luminal
subtypes, showed that a molecular urothelial differ-
entiation program was maintained even in those
luminal tumors that had lost morphological differenti-Cell Reation. Study of the genomic alterations associated
with this component coupled with functional studies
revealed a protumorigenic role for PPARG in luminal
tumors. Our results support the inclusion of ICA in the
exploitation of multiscale data sets.
INTRODUCTION
Large-scale projects (e.g., Cancer Genome Project [CGP],
The Cancer Genome Atlas [TCGA], or the International Cancer
GenomeConsortium [ICGC]), and the efforts of individual labora-
tories, are generating massive amounts of high-throughput
molecular data often associated with clinicopathological charac-
teristics. Transcriptome data for tumors are the most commonly
available type of large-scale molecular data. These remain diffi-
cult to interpret because the transcriptome is influenced by
various overlapping biological factors linked to the tumor cells
or to the tumor microenvironment and nonbiological factors
linked to sample processing or data generation. The need to de-
convolute these factor effects led to the use ofmethods originally
developed to solve the blind source separation problem (Jutten
and He´rault, 1991), with the aim of recovering hidden signalports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1235
sources from the observed output mixture. Independent compo-
nent analysis (ICA) is one of these methods. ICAmodels the level
of expression of each gene in a given sample as a linear weighted
sum of several independent components, where each compo-
nent captures the effect of one of the factors/processes. The
expression data matrix is thus decomposed into a number of
components, each of which is characterized by an activation
pattern both across genes and across samples. The genes
with the largest projection onto a component (providing the
greatest contribution) are the genes the most strongly influenced
by the process associated with this component. The contribution
value of a sample reflects the activity of the component in this
sample. Most of the studies applying ICA to cancer transcrip-
tome data have focused on the interpretation of components
based on the contribution of the genes to the components
(Liebermeister, 2002; Lee and Batzoglou, 2003; Carpentier
et al., 2004; Chiappetta et al., 2004; Frigyesi et al., 2006;
Teschendorff et al., 2007). No study, to our knowledge, has
interpreted ICA results taking into account additional data
associated with the samples, such as clinical and pathological
data (including histopathological images), mutations and copy
number alterations, and conditions of procurement and pro-
cessing of the samples.
Bladder cancer is one of the most common cancers in North
America and Europe (Ferlay et al., 2010). The stage classification
differentiates between non-muscle-invasive (CIS [carcinoma
in situ], Ta, T1) and muscle-invasive tumors (T2, T3, T4). Gene
expression clustering is commonly used to identify subtypes in
cancer with the aim of gaining new insights into the molecular
heterogeneity of tumors and of improving the management
of cancer patients. Recently, basal and luminal subtypes of
muscle-invasive bladder cancer that shared molecular features
with basal and luminal breast cancers have been identified
(Sjo¨dahl et al., 2013; Choi et al., 2014; Cancer Genome Atlas
Research Network, 2014; Damrauer et al., 2014; Rebouissou
et al., 2014).
We show here that by applying ICA to bladder cancer
transcriptome data sets, exploiting additional molecular and
clinicopathological data, and comparing to ICA applied to multi-
ple cancer types, it is possible to obtain insights into bladder
carcinogenesis.
RESULTS
ICA Applied to the CIT Bladder Cancer Transcriptome
Data Set: Interpretation of Components Based on Gene
Projections
ICA was applied to our reference data set, which was produced
in the framework of the French national Cartes d’Identite´ des
Tumeurs (CIT) program from a series of 198 tumors and three
normal samples (CIT series). These 198 tumors comprised
both non-muscle-invasive tumors (n = 106) (deposited in Ar-
rayExpress, accession number E-MTAB-1940) andmuscle-inva-
sive tumors (n = 92) (E-MTAB-1803, Rebouissou et al., 2014).
Twenty independent components (ICs) were computed.
The first interpretation of each component was based on anal-
ysis of the genes with the largest projections on the component
(the contributing genes, the most strongly influenced by the pro-1236 Cell Reports 9, 1235–1245, November 20, 2014 ª2014 The Autcess associatedwith this component; Table S1).We investigated
the association of the component with a specific cell type, known
pathways, or sets of coregulated genes, by studying the
enrichment of these contributing genes in predefined gene sets
(such as Gene Ontology, KEGG, or BioCarta, see Supplemental
Experimental Procedures). We also investigated whether these
genes were located in a particular chromosomal region or could
be distinguished in terms of sequence features, such as GC
content.
Eleven components were associated with a biological
process on the basis of enrichment analysis (Tables 1, S2 and
S3, sheet ‘‘Association_ICs_genomicLocation’’). Among these
components, we were able to distinguish between components
associated with the tumor cells and components associated
with the tumor microenvironment. Three of the tumor cell-driven
components were linked to various types of differentiation (squa-
mous and basal differentiation [CIT-6], urothelial differentiation
[CIT-9], neural differentiation [CIT-18]), one was associated with
the cell cycle (CIT-7), one was associated with mitochondria
(CIT-4), and another (CIT-10) contained six neighboring genes
located at 11p15.5, including the IGF2/H19 imprinted locus (Fig-
ure S1A). Three components were associated with the stroma:
CIT-3 was assigned to smooth muscle, CIT-8 to the immune
response mediated by B and T lymphocytes, and CIT-12 to
tumor-associated myofibroblasts. Two biologically interpretable
components could not be attributed to either tumor cells or
the stroma (CIT-5, CIT-14). CIT-5 was enriched in interferon
response genes and CIT-14 was enriched in inflammatory and
early response genes. One component, CIT-2, was not signifi-
cantly enriched in any particular gene set, but gene projections
onto this component were strongly correlated with GC content
of the corresponding genes (Figure S1B).
ICA Applied to the CIT Bladder Cancer Transcriptome
Data Set: Interpretation of the Components Based on
Contributions of the Tumor Samples
We further interpreted the components by studying the
association of each component with specific tumor sample
features by analyzing the values of sample contributions to
the components (Table S3, sheet ‘‘Sample_Contributions’’, and
Figure S1).
The samples of the CIT series were comprehensively anno-
tated (Table S3, sheet ‘‘Sample_Annotations’’) for clinical and
pathological data, the mutational status of the genes most
commonly mutated in bladder cancer, genomic alterations as-
sessed by CGH array, transcriptomic signatures (the carcinoma
in situ signature (Dyrskjøt et al., 2004), and the multiple regional
epigenetic silencing phenotype (MRES phenotype) (Vallot et al.,
2011)) and technical factors.
We investigated the distributions of the tumors of theCIT series
on the components as a function of these parameters (Table S3,
sheet ‘‘Association_Annotation_ICs’’). This approach enabled
us to interpret two additional components (CIT-1 and CIT-13)
and deepened our understanding of two components previously
assigned based on gene contributions (CIT-14 and CIT-18).
CIT-13 was associated with the two well-known pathways
of bladder tumor progression (Figure 1A). Indeed, most of the
tumors displaying a negative contribution to CIT-13 were Tahors
Table 1. Interpretation of the Independent Components of the CIT Bladder Cancer Data Set Using the Contributing Genes
Source
Component Contributing
Genes (n) Interpretation of the Contributing GenesID Name
Tumor cells CIT-6 basal-like 151 enriched in gene sets ‘‘keratinization,’’ ‘‘keratinocyte differentiation’’;
markers of epithelial basal cells: KRT5, KRT6A, KRT14, KRT16, KRT17,
DSC3, etc.
CIT-4 mitochondria 61 enriched in mitochondrial genes
CIT-7 cell cycle 187 enriched in targets of E2F and genes involved in cell cycle
markers of proliferation: TOP2A, CDC20, CCNB2, CDK1, BUB1B, AURKA,
kinesins (KIF4A, KIF2C, KIF14, KIF15, KIF11, KIF20A, KIF23, KIFC1), etc.
CIT-9 urothelial
differentiation
181 markers of urothelial differentiation: UPK1A, UPK1B, UPK2, KRT20, PPARG,
BAMBI. TFs involved in differentiation: FOXA1, GATA3, GRHL3
CIT-10 11p15.5 163 five genes colocalized at 11p15.5 (H19, SYT8, TNNT3, TNNI2, LSP1)
CIT-13 bladder cancer
pathwaysa
175
CIT-18 neuroendocrineb 122 enriched in neuronal genes: CELSR2, CELSR3, ENO2, EMX2, NMU, etc.
Stroma CIT-3 smooth muscle 197 enriched in targets of the serum response factor SRF, and in gene sets
associated with smooth muscle
markers of the smooth muscle: calponin 1 (CNN1), synemin (SYNM), actins
(ACTG2, ACTC1, ACTA2), myosins (MYL9, MYLH11), desmin (DES),
transgelin (TAGLN), etc.
CIT-8 lymphocytes
B&T (LB&T)
211 enriched in gene sets associated with immune reaction
markers of lymphocytes (immunoglobulins, chemokines, members of the
MHC class II, CD79A, POU2AF1, and markers of T cells CD2, CD53, CD3D,
CD8A, GZMA, GZMB, LCP2, TNFRSF17, etc.)
CIT-12 myofibroblasts 192 enriched in gene sets associated with extracellular matrix
markers ofmyofibroblasts: periostin (POSTN,) lumican (LUM), decorin (DCN),
collagens (COL1A1, COL1A2, COL5A1, COL5A2, COL6A2, COL6A3,
COL15A1, COL3A1, COL12A1), etc.
Tumor cells
or stroma
CIT-5 interferon
response (IFN)
169 enriched in targets of interferon regulatory factors IRF1, IRF2, IRF7, IRF8, and
the TF STAT1. Among the first 25 contributing genes, 11 encode interferon-
induced proteins IFIT1, IFIT3 IFI6, IFI27, IFI35, IFI44, IFI44L,MX1,MX2, IFI6,
IFIH1. IRF9 is also a contributing gene. The presence ofMX1 and CXCL10 in
the contributing genes indicates a type I interferon response.
Involvement of
technical factors
CIT-1 batch effecta 147
CIT-2 GC content 32 the projection values of all genes are highly correlated to their GC content
(Pearson correlation = 0.66)
CIT-14 inflammation/early
response/type
of surgeryb
173 enriched in genes involved in inflammatory response and response to stress
contributing genes including chemokine genes (CXCL1, CXCL2, CXCL3),
early response to stress genes (EGR1, EGR2, EGR3, IER3), interleukin genes
(IL8, IL1A), FOS, FOSB, DUSP1, and DUSP5
See also Figure S1 and Tables S1 and S2.
aAssignation of components using tumor contribution.
bFurther assignation of components using tumor contribution.papillary tumors, frequently mutated for FGFR3 (Figure 1B), the
marker of the Ta pathway. Conversely, the tumors displaying
a positive contribution to CIT-13 were mostly T2-4 tumors, with
high rates of TP53 mutation, expressing markers preferentially
associated with the CIS pathway (the CIS signature and the
MRES phenotype) (Figure 1B). T1 tumors were found on both
sides of the component (Figure 1B). The distribution of the tu-
mors on CIT-13 was therefore entirely consistent with the defini-
tion of the two pathways of bladder tumor progression. CIT-1
was not associated with any biological information. The trace-Cell Reability of processing for the CIT samples made it possible to attri-
bute this component to a batch effect (Figure S1C).
The strongest association for component CIT-14 was with the
type of surgery (transurethral resection of the bladder tumor
versus cystectomy) (p = 1.89 3 1017, Table S3, sheet ‘‘Asso-
ciation_Annotation_ICs’’; Figure S1D). The enrichment of the
contributing genes of CIT-14 in early response genes (Table 1)
may therefore in part reflect the different stresses induced by
the two different surgical procedures. The enrichment of CIT-14
in genes previously reported as differentially expressed inports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1237
AB
Figure 1. Association of the CIT-13 Component with the Two Pathways of Bladder Tumor Progression
(A) The two pathways of bladder tumor progression (Ta pathway and CIS pathway). Ta tumors constitute the largest group of bladder tumors (50%) at first
diagnosis. Ta tumors often recur but only rarely progress via T1 tumors to muscle-invasive tumors (T2–T4 tumors). The Ta pathway is characterized by a high
frequency of FGFR3mutations. The other pathway corresponds to the carcinoma in situ (CIS) pathway. CIS often progress (in about 50%of cases) to T1 and then
to muscle-invasive tumors. This pathway is characterized by early TP53mutations (Spruck et al., 1994), a specific transcriptomic signature (Dyrskjøt et al., 2004),
and an epigenetic phenotype (MRES, Vallot et al., 2011). For box plots, the bottom, top, and middle bands of the boxes indicate the 25th, 75th, and 50th per-
centiles, respectively. Whiskers extend to the most extreme data points no more than 1.5 interquartile range from the box.
(B) Distribution of the tumors on the CIT-13 component as a function of pathological and molecular characteristics. The histogram of the sample contributions to
CIT-13 is shown on the left. The sample contribution values are given on the vertical axis. On this axis is also shown the expression level of one of the strongest
contributing genes (ANXA10) of the IC, each point representing one tumor sample, and its color indicating the relative level of expression of the gene. The color
scale for the expression level of ANXA10 is shown below. The box plots and superimposed individual data points show the distribution of the samples on CIT-13
as a function of stage (Ta, T1, and tumors of higher stage: T2–T4), FGFR3 and TP53mutation status, the CIS transcriptomic signature (Dyrskjøt et al., 2004), and
the multiple regional epigenetic silencing (MRES) phenotype (Vallot et al., 2011). The normal samples are represented as green diamonds. False discovery rates
(FDRs) for Kruskal-Wallis tests are provided at the top of each plot.
See also Table S3.prostate cancers as a function of sample type (biopsy versus
prostatectomy specimens) (Lin et al., 2006) supports this conclu-
sion (Table S2, sheet 1). We cannot exclude the possibility that
a biological process not directly related to the type of surgery
may also contribute to this component, which we refer to as
the inflammation/early response/type of surgery. The CIT-18
component, which was enriched in neural genes (Table 1), was
due to the presence of neuroendocrine tumors in the CIT series
(Figure S1E).
Representative pathological sections were available for the
CIT tumor series. For each component, the sections were ranked
according to the contribution of the corresponding tumor sam-
ple to the component (http://microarrays.curie.fr/publications/
UMR144/LuminalBasalBladder/) and were reanalyzed in this
context. This confirmed the assignment of components CIT-3,
CIT-12, and CIT-7 to smooth muscle, myofibroblasts, and cell
cycle, respectively (Figure S2).1238 Cell Reports 9, 1235–1245, November 20, 2014 ª2014 The AutICA of Multiple Transcriptome Data Sets, Bladder,
and Other Types of Cancer Allows Distinguishing
Reproducible Cancer Type-Specific Components and
Components Common to Different Cancer Types
We investigated the reproducibility of the components retrieved
from our reference bladder tumor set (CIT series), by applying
ICA to seven other bladder cancer transcriptome data sets, six
series of breast carcinomas and eight series of carcinomas of
various types (colon, rectum, endometrium, kidney, lung squa-
mous cell and lung adenocarcinoma, ovary, prostate). The
data sets, their accession numbers, and gene projections for
all data sets are given in Table S4.
We used a correlation graph approach to compare the ICs
across the different data sets (see Supplemental Experimental
Procedures) (Figure 2). In the correlation graph, each node rep-
resents a component computed for a data set, and each edge
connects two components if the corresponding gene projectionshors
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Figure 2. Comparison of the Independent Components across Data Sets of Various Cancer Types Using Correlation-Based Graphs
Correlation-based graph of the independent components (ICs) calculated for seven bladder cancer data sets plus 14 other gene expression data sets of different
types of cancer, including six breast carcinoma data sets and one data set for each of the following cancer types: prostate, colon, and rectum adenocarcinomas,
uterine corpus endometrioid carcinoma, kidney (clear cell carcinomas), lung (squamous cell carcinomas and adenocarcinomas), and ovarian serous adeno-
carcinomas. Each node denotes an IC; the node colors indicate the type of cancer, whereas their shapes distinguish between data sets of the same cancer type.
The numerical IDs indicate the order in which the ICs were returned by the icasso method. The graphs were visualized with Cytoscape (Cline et al., 2007). The
edge thickness indicates the degree of correlation between the two ICs linked by the edge. Only pairs of ICs with absolute correlation values exceeding 0.35 are
shown. Reciprocal edges are colored black, whereas non-reciprocal edges are in gray. Reproducible components appear on the graph as a cluster of tightly
interconnected nodes. See also Tables S4 and S5.are correlated. Clusters of components (pseudocliques, see
Supplemental Experimental Procedures) were observed in the
structure of the correlation graph (the genes contributing to the
components of each clique are given in Table S5). Some clusters
were composed of densely interconnected nodes and included
components common to most types of cancer (immune
response mediated by B and T lymphocytes, cell cycle, GC con-
tent, myofibroblasts/smooth muscle). Other clusters were com-
mon to some, but not all types of cancer (including gender,
basal-like, mitochondria, interferon response, inflammation/
early response genes/type of surgery-associated clusters).
Because we used several data sets for bladder and breast can-
cers, we were able to identify pseudocliques specific to these
cancers. Two bladder-cancer-specific pseudocliques consisted
of components found in all bladder cancer data sets: one was
associated with urothelial differentiation, whereas the other
was associated with the two pathways of bladder tumor
progression.Cell ReAssociation of theRecently IdentifiedExpression-Based
Subtypes of Muscle-Invasive Bladder Cancer with
Biological Processes
Muscle-invasive bladder cancers are clinically and biologically
heterogeneous. Recently, expression-based clusters that
resembled basal and luminal subtypes of breast cancer have
been reported in muscle-invasive bladder cancer (Sjo¨dahl
et al., 2013; Cancer Genome Atlas Research Network, 2014;
Choi et al., 2014; Damrauer et al., 2014; Rebouissou et al.,
2014). To characterize these muscle-invasive bladder cancer
subtypes, we compared their distribution on the different
components, which had been interpreted in the CIT series. We
studied the four subtypes from the TCGA classification (Cancer
Genome Atlas Research Network, 2014): cluster I (papillary
luminal), cluster II (luminal), cluster III (basal-like), and cluster
IV. These four clusters were identified in the CIT series using a
centroid-based predictor (see Supplemental Experimental Pro-
cedures). The six components displaying the most significantports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1239
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Figure 3. Characterization in the CIT Series of the Four Gene Expression Subtypes as Defined in the Bladder Cancer TCGA 2014 Classifi-
cation
Cluster I (papillary luminal, in darkmagenta), cluster II (luminal, inmagenta), cluster III (basal-like, in yellow), and cluster IV (orange). The six components displaying
the most significant differences between these subtypes as well as the progression pathway component are shown.
(A) Each box plot represents the distribution of a subgroup of tumors on the IC and is overlaid with the individual data points. The vertical lines at the left of the box
plots indicate the expression level of one of the strongest contributing genes of the IC, each point representing one tumor sample, and its color indicating the
relative level of expression of the gene. For box plots, the bottom, top, and middle bands of the boxes indicate the 25th, 75th, and 50th percentiles, respectively.
Whiskers extend to the most extreme data points no more than 1.5 interquartile range from the box. The diamond-shaped green points indicate the positions of
the normal samples. FDR values for Kruskal-Wallis tests are provided at the top of each plot. The p values (Wilcoxon test) for each pairwise comparison are shown
at the bottom of each plot: *0.01% p < 0.05; **0.001% p < 0.01; ***p < 0.001.
(B) Heatmap representing the median of the sample contributions of each subtype to the components. For the purpose of this figure, the vector of sample
contributions of some components (lymphocytes, interferon response, urothelial differentiation, basal-like) has been reversed such that the over- (respectively,
under-) expression of the most contributing genes of the components are on the positive (respectively, negative) side of the component and thus appear in red
(respectively, blue) color.
See also Figure S2 and Table S3.differences between these clusters and the progression pathway
component are shown in Figure 3A. As expected, basal-like tu-
mors presented a basal differentiation (their distribution on the
basal-like component [CIT-6] corresponded to high expression
of basal markers, such as KRT6A), and a low level of urothelial
differentiation (their distribution on the urothelial differentiation
component (CIT-9) corresponded to low expression of urothelial
differentiation markers, such as KRT20). We also showed that
this subtype presented a strong interferon response (as shown1240 Cell Reports 9, 1235–1245, November 20, 2014 ª2014 The Autby its distribution on the interferon-response component
[CIT-5]). The distribution of basal-like tumors on the component
associated with the bladder cancer pathways (CIT-13) was
similar to that of TP53-mutated tumors and different from that
of FGFR3-mutated tumors, suggesting that basal-like tumors
belonged to the CIS pathway (see diagram in Figure 1A). Their
distribution on the components associated with stroma (CIT-3
[smooth muscle component], CIT-8 [lymphocytes T and B
component], and CIT-12 [myofibroblast component]) indicatedhors
that basal-like tumors were relatively poor in smooth muscle
cells and lymphocytes T and B and relatively rich in myofibro-
blasts (strong expression of myofibroblast markers). The two
luminal subtypes (clusters I and II) presented a high level of dif-
ferentiation. Indeed, their distribution on the urothelial differenti-
ation component (CIT-9) corresponded to high expression of
urothelial differentiation markers, such as KRT20. These two
subtypes differed in terms of stroma, cluster II was richer in
smooth muscle (CIT-3) and myofibroblasts (CIT-12). A sche-
matic representation summarizing the characteristics of each
subtype according to the components is shown in Figure 3B.
Genetic and Functional Evidence for a Role of PPARG in
Urothelial Differentiation and in Bladder Carcinogenesis
The urothelial differentiation component (CIT-9), found in all
bladder cancer data sets studied, was specifically associated
with bladder luminal tumors. We studied this component in
more detail.
Most luminal tumors (subtypes I and II) were distributed on the
differentiated side of the component (high expression of differen-
tiation markers such as KRT20, GRHL3, UPK1A, BAMBI, and
PPARG) (Figure 4A). As expected, Ta low-grade tumors (G1/
G2) were on the differentiated side of the component (Figure 4A)
and were differentiated at the morphological level (Figure 4B;
http://microarrays.curie.fr/publications/UMR144/
LuminalBasalBladder/). Surprisingly the tumors with the highest
levels of urothelial differentiation markers (most negative contri-
butions to the component) were high-grade tumors (G3) (Fig-
ure 4A). By morphology, these tumors both lacked architectural
organization and displayed unpolarized and atypical nuclei
(Figure 4B; http://microarrays.curie.fr/publications/UMR144/
LuminalBasalBladder/). These observations indicate that there
was no relationship between molecular differentiation measured
on this component and morphological grade assessed by archi-
tectural organization and nuclear atypia.
To identify protumorigenic genes potentially involved in the
carcinogenesis of luminal tumors, we looked for altered genomic
regions associated with the urothelial differentiation component.
Among these regions, we selected the regions of gains that were
found in tumors associated with the differentiated side of the
component and that contained a contributing gene associated
with differentiation. In the CIT series, a region of genomic
alteration (chr3:1650731-12883379) encompassing PPARG, a
contributing gene associatedwith urothelial differentiation (Table
S6) was the most significantly associated with the component.
The alterations observed in this region were mostly gains (in 51
of the 178 tumors, 29%; with losses observed in seven of the
178 tumors, 4%) (Figure 4C). Computation of the minimal region
of gain (Rouveirol et al., 2006) (see Supplemental Experimental
Procedures) identified a 774 kb region containing nine genes,
including PPARG. These genomic alterations of PPARG were
correlated with its expression in both tumors and bladder tu-
mor-derived cell lines (Figure S3A). The use of high-resolution
SNP arrays (Illumina Human 610) for 11 tumors presenting a
gain of this region made it possible to narrow down the minimal
region of gain to 273.9 kb including only PPARG. The distribution
of the tumors of the TCGA series on the urothelial differentiation
component according to genomic alterations confirmed thatCell RePPARG gains were associated with differentiated tumors (Fig-
ure S3B). These findings provide genetic evidence that PPARG
was involved in tumorigenesis of these tumors. Consistent with
this, pathway enrichment analysis of the contributing genes of
the urothelial differentiation component showed enrichment in
genes of the PPAR pathway: PPARG, FABP4, HMGCS2,
ACSL5, ACOX1, APOA2, and ACOX3 (Table S2, sheet ‘‘CIT9-
GOstat’’). To demonstrate the functional involvement of PPARG
in bladder tumors, we studied the effect of small interfering RNA
(siRNA)-mediated PPARG knockdown on the growth of nine
bladder-cancer-derived cell lines with different levels of PPARG
mRNA. Two different siRNAs targeting PPARG mRNA were
used, and a downregulation of 65%–90% of PPARG mRNA
was obtained (Figure S3C). The largest decrease in cell viability
(50%) was observed for the two cell lines presenting a genomic
alteration of PPARG (amplification for UMUC9 and gain for
SD48) (Figure 4D, left panel). Overall, PPARG mRNA level was
significantly correlated with the effect of siRNA-mediated
PPARG knockdown, because higher levels of PPARG expres-
sion were associated with larger decreases in cell viability (Fig-
ure 4D, right panel). We also investigated the effect of PPARG
knockdown on the cloning efficiency of three cell lines (SD48,
UMUC9, and MGHU3). The inhibition of growth in the soft agar
assay was similar (60% for cell lines with PPARG genomic alter-
ation, SD48, and UMUC9, and 20% for MGHU3) to the decrease
in cell viability in 2D culture (Figure 4E). These results indicated
that PPARG was involved in tumor cell growth in PPARG ex-
pressing bladder cancer cells.
PPARG is a transcription factor of the nuclear receptor type 1
subfamily and has been implicated in urothelial differentiation
(Varley et al., 2004). The presence of PPAR target genes among
the contributing genes of the urothelial differentiation component
suggested that PPARG could control the expression of several
contributing genes of this component. We tested this hypothesis
by comparing the transcriptome of the SD48 cell line treated with
three different siRNAs targeting PPARG or with the transfection
reagent (Lipofectamine). We found that 198 genes were signifi-
cantly deregulated by siRNA treatment (107 genes significantly
downregulated and 91 genes upregulated) (Table S7). This set
of deregulated genes was significantly enriched (Fisher’s test,
p < 0.0001) in genes contributing to the CIT urothelial differenti-
ation component (21 of 198; Figure 4F; Table S7). Most of the 21
genes of the urothelial differentiation component controlled by
PPARGwere upregulated by this transcription factor (downregu-
lation observed upon PPARG knockdown for 18 of these 21
genes) and, as expected, were associated with differentiation
(17 of these 18 genes). Conversely, two of the three genes down-
regulated by PPARG (upregulated following PPARG knock-
down) were associated with undifferentiated tumors.
DISCUSSION
We applied independent component analysis (ICA) to 21 tran-
scriptome data sets, including eight data sets for bladder cancer
and five for breast cancer. For one of the bladder cancer data
sets (the CIT data set that was generated by our group), clinical,
pathological, molecular, and sample processing data were avail-
able. The use of these additional data made it possible to assignports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1241
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Figure 4. Identification of PPARG as an Oncogene Controlling Cell Viability and Differentiation in Bladder Tumors
(A) Heatmap of the top 15 contributing genes of CIT-9; the genes (rows) and samples (columns) are ranked according to their contribution to the component. The
gene expression profiles are centered. These top 15 most contributing genes include several urothelial differentiation markers (KRT20, GRHL3, UPK1A, BAMBI,
PPARG). The stage, grade, and TCGA tumor subtype classification (I, papillary luminal; II, luminal; III, basal-like; IV) are indicated.
(B) Histopathological sections of two tumors on the differentiated side of the component (high expression of urothelial differentiation markers). Case #90, a T1G3
tumor, despite having one of the highest levels of urothelial differentiation markers lacked any architectural organization and displayed unpolarized and atypical
nuclei. Case #263, a TaG2 tumor, which was also on the differentiated side of the component, was differentiated at the morphological level.
(C) Distribution of the tumor samples according to their alteration status for the region on chromosome 3:1650731-12883379 encompassing PPARG, as
measured by aCGH. FDR value for the Kruskal-Wallis test is provided at the top of the box plot. For box plots, the bottom, top, and middle bands of the boxes
indicate the 25th, 75th, and 50th percentiles, respectively. Whiskers extend to the most extreme data points no more than 1.5 interquartile range from the box.
(D) Left: effect of PPARG knockdown on cell viability, as assessed by MTT assays, of nine bladder-cancer-derived cell lines. Two different siRNAs were used.
Right: correlation between cell viability inhibition induced by PPARG knockdown (mean of the two different siRNAs) and PPARG expression.
(E) Effect of PPARG knockdown on anchorage-independent colony formation in soft agar. The values reported are the means ± SD of three independent
experiments carried out in triplicate.
(F) Heatmap visualization of the 198 regulated transcripts in SD48 cells 96 hr after PPARG knockdown by three different siRNAs. The expression ratio (FC) was
determined for each gene by comparison of the mean level of expression on lipofectamine control (LPF) chips with that on PPARG siRNA chips. The gene
expression profiles are centered on the mean level of expression on control chips. For regulated genes contributing to the CIT-9 component with an absolute
value for the contribution score exceeding 3 (n = 21), the contribution score is indicated according to the color scale on the left side of the heatmap.
See also Figure S3 and Tables S3, S6, and S7.several components to a biological process or to technical fac-
tors and allowed us to characterize subtypes of tumors and to
identify molecular mechanisms associated with a component.
Our analysis across different types of cancer identified both
components common to some or all cancer types considered,
and also components specific to a particular type of cancer.1242 Cell Reports 9, 1235–1245, November 20, 2014 ª2014 The AutThree components common to all cancer types (B and T lympho-
cytes, cell cycle, myofibroblasts) probably correspond to the
three multicancer gene signatures/attractors (lymphocyte-spe-
cific, mitotic chromosomal instability, and mesenchymal transi-
tion) identified very recently in breast, colon, and ovarian cancer
by a different computational approach (Cheng et al., 2013).hors
Indeed, many of the genes associated with these components
were also found to be markers for these signatures. The smooth
muscle and myofibroblasts components were merged in some
data sets (the TCGA and Kim et al., 2010 bladder data sets
and in the lung adenocarcinoma data set), indicating that the
expression of these two stroma components are closely related
and are often present in the same samples for these data sets.
The components common to some but not all cancer types
included the basal-like component. This component was found
in bladder cancer, lung squamous carcinoma, lung adenocarci-
noma, and endometrioid carcinoma and was related to a
component specific to breast cancer, the basal component.
The existence of a basal subgroup in breast cancer is widely
recognized (Bertucci et al., 2012; Sørlie et al., 2001). It is
becoming clear that basal-like subgroups also exist in other can-
cer types (Chung et al., 2004; Wilkerson et al., 2010; Di Palma
et al., 2012), including, as shown very recently, bladder cancer
(Sjo¨dahl et al., 2013; Cancer Genome Atlas Research Network,
2014; Choi et al., 2014; Damrauer et al., 2014; Rebouissou
et al., 2014).
TCGA results have shown that most colon and rectum ade-
nocarcinomas cannot be distinguished at the genomic level
(Cancer Genome Atlas Network, 2012). Consistent with this
observation, adenocarcinomas of the colon and the rectum
shared most of their components in our analysis.
The biologically meaningful ICs we identified included four
related to tumor microenvironment. A detailed interpretation of
these components should help to characterize the tumor micro-
environment and the reciprocal interactions between cancer
cells and stromal cells.
Luminal tumors differed from the other bladder tumors by their
activities on different components: low interferon response and
the presence of molecular urothelial differentiation. Surprisingly,
molecular urothelial differentiation was maintained even in those
luminal tumors that had lost morphological differentiation, as
assessed by cytological atypia and the absence of architectural
organization. This suggests a dependency on part of the
differentiation program for tumor progression. We demonstrated
that the transcription factor PPARG positively controls the
expression of genes linked to molecular differentiation in tumor
cells. In agreement with this, Choi et al. (2014) have recently
shown a PPARG activation signature in luminal tumors. In addi-
tion, we provide here genetic and functional evidence that this
gene is involved in tumorigenesis of molecularly differentiated
bladder tumors. Interestingly, the use of pioglitazone, an anti-
type 2 diabetic drug that is an agonist of PPARG, has been asso-
ciated with an increased risk of bladder cancer (Turner et al.,
2014). This could be due to the protumorigenic role of PPARG,
as shown here. A parallel can be drawn between PPARG and
another nuclear receptor also associated with differentiation,
the estrogen receptor. Indeed, the estrogen receptor is associ-
ated with differentiation in the breast, which is necessary for
the growth of estrogen receptor-positive tumors, and the use
of estrogen increases the risk of breast cancer (Collaborative
Group on Hormonal Factors in Breast Cancer, 1997).
There are several advantages of searching for associations
between expression and copy number through ICA, as we did
here to find PPARG, rather than using a classical search for cor-Cell Rerelation between expression and copy number. The association
between a genomic alteration and a component can be directly
interpreted in the context of a biological process (represented by
the component) and of multiple genes associated with this bio-
logical process (the most contributing genes on the component),
rather than simply associating one genomic alteration with one
gene. Moreover, it reduces the high number of candidates that
can be obtained when analyzing the genomic alterations alone.
We also found that genomic gains of GATA3 were associated
with the urothelial differentiation component (data not shown).
GATA3 is important for the proliferation of luminal breast tumors
(Kong et al., 2011) and is therefore likely to play the same role in
bladder tumors presenting a molecular urothelial differentiation.
We have developed an R package (MineICA, available in
Bioconductor: http://www.bioconductor.org/packages/release/
bioc/html/MineICA.html) that implements most of the methods
used in our study. We also provide a bladder tumor data set
that contains not only molecular and anatomoclinical data but
also histological data. Integrating image data into multiparamet-
ric analyses of tumors is an emerging domain of research. The
resource we provide should be useful in this respect.
Our analysis shows that applying ICA to transcriptome data
and exploiting clinical, pathological, and genetic alteration data
obtained from ongoing large-scale projects will provide insights
into cancer biology.
EXPERIMENTAL PROCEDURES
CIT Series: Tissues Samples and Data
Tissues samples of human bladder carcinomaswere collected from patients at
Henri Mondor Hospital (Cre´teil, France), Institut Gustave Roussy (Villejuif,
France), and Foch Hospital (Suresnes, France). Details of samples and
large-scale data are provided in Supplemental Experimental Procedures. All
patients provided written informed consent, and the study was approved by
the ethics committees of the different hospitals involved in the study (Comite´
de Protection des Personnes de l’ho^pital Henri Mondor, Comite´ de Protection
des Personnes de Boulogne - Ambroise Pare´ and Comite´ de Protection des
Personnes de Bice^tre). All analyses were performed on the basis of anony-
mized patient data.
Bioinformatics Analysis
To compute the independent components, we applied the FastICA algorithm
(Hyva¨rinen, 1999) to each data set using icasso (Himberg et al., 2004) for
selecting stable components. We computed 20 independent components
(ICs), using pow3 nonlinearity and deflationary algorithm. We interpreted the
genes associated with an IC (‘‘most contributing genes’’) by performing enrich-
ment analysis with GOstats (Falcon and Gentleman, 2007) and ‘‘GSEA Pre-
ranked’’ module (Subramanian et al., 2005). We compared the contributions
of predefined groups of tumors to the ICs in Wilcoxon rank-sum and Krus-
kal-Wallis tests. The ICs were compared across data sets using correlation-
based graphs.
Details of computational analyses are provided in Supplemental Experi-
mental Procedures.
Experiments
To study the role of PPARG in bladder-cancer-derived cell lines, we evaluated
the effect of PPARG knockdown using siRNAs on cell viability of nine cell lines
(J82, KK47, MGHU3, SCaBER, SD48, RT112, UMUC3, UMUC6, UMUC9) and
on colony formation in soft agar for three of these cell lines (MGHU3, SD48,
UMUC9). PPARG mRNA expression level was determined using quantitative
RT-PCR. Genes regulated after PPARG knockdown were determined using
Affymetrix DNA microarray. Details of experimental procedures and statistical
analysis of the results are provided in Supplemental Experimental Procedures.ports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1243
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http://dx.doi.org/10.1016/j.celrep.2014.10.035.
AUTHOR CONTRIBUTIONS
A.B., A.Z., and E.B. designed the computational methodology. A.B. assem-
bled the data and performed the ICA analyses. A.B. implemented tools for
data visualization and interpretation in cooperation with F.R. P.G. and E.B.
advised on processing the data and tools implementation. A.B., F.R., and
A.Z. were responsible for the interpretation of the independent components,
helped by I.B.-P., S.R., and J.S. L.G. participated in TCGA data analysis and
in the analysis of correlation graph. A.B., A.K., A.Z., and A.d.R. compared
CIT and TCGA data. I.B.-P. designed and was responsible for the functional
validation studies. C.K., Y.L., Y.N., and I.B.-P. performed the experimental
validation studies, and A.K. was involved in their analysis. Y.A., E.C., and
I.B.-P. prepared and analyzed histopathological data. Y.A. was responsible
for the anatomopathological data and image interpretation, T.L. and S.B. for
the clinical data, and C.R.-P., N.L.-P., Y.N., and I.B.-P. for discussing the ther-
apeutic applications of the work. A.B., I.B.-P., F.R., and A.Z. wrote the manu-
script. A.Z. supervised the computational work. F.R. coordinated the work. All
authors discussed the results and implications and reviewed the manuscript.
ACKNOWLEDGMENTS
This work is part of the ‘‘Cartes d’Identite´ des Tumeurs’’ (CIT) program funded
and developed by the ‘‘Ligue Nationale contre le Cancer’’ (LNCC) (http://cit.
ligue-cancer.net). We thank E. Voirin, N. Servant, G. Lucotte, and P. Hupe´
for their help with bioinformatics data management and analysis. We thank
members of the bladder cancer CIT consortium (P. Maille´ and D. Vordos, Henri
Mondor Hospital; M. Sibony, Cochin Hospital; A. Laplanche, IGR, INSERM; Y.
Denoux and V. Molinie´, Foch Hospital; E. Letouze´, LNCC) for their constant
support. This work was supported by the LNCC (to ‘‘Oncologie Mole´culaire’’
and ‘‘Computational Systems Biology of Cancer’’ accredited teams), the Insti-
tut Curie (to F.R., E.B., A.Z.), the ‘‘Centre National de la Recherche Scientifi-
que’’ (CNRS) (to F.R.), the ‘‘Institut National de la Sante´ et de la Recherche
Me´dicale’’ (INSERM) (to E.B., A.Z., S.B., and Y.A.), the INCa (INCa_2960 and
4382 to F.R. and Y.A.), ITMO cancer, systems biology program (to A.Z.,
E.B., and F.R.), the Labex (no. ANR-10-LBX-0038) part of the IDEX PSL (no.
ANR-10-IDEX-0001-02 PSL) (to F.R.), and York Against Cancer (to J.S.).
A.B. was supported by a grant from the INCa, from the LNCC, and by NIH grant
5U24 CA143799-04 as part of TCGA project, Y.L. by a grant from the ‘‘Fonda-
tion Franco-Chinoise pour la Science et ses Applications’’ (FFCSA), Y.N. by a
grant from the ‘‘Fondation ARC pour la recherche sur le cancer,’’ and A.K. by a
grant from the LNCC. The results published here are in part based upon data
generated by the TCGA Research Network: http://cancergenome.nih.gov/.
Received: January 25, 2014
Revised: August 18, 2014
Accepted: October 13, 2014
Published: November 13, 2014
REFERENCES
Bertucci, F., Finetti, P., and Birnbaum, D. (2012). Basal breast cancer: a com-
plex and deadly molecular subtype. Curr. Mol. Med. 12, 96–110.
Cancer Genome Atlas Network (2012). Comprehensive molecular character-
ization of human colon and rectal cancer. Nature 487, 330–337.1244 Cell Reports 9, 1235–1245, November 20, 2014 ª2014 The AutCancer Genome Atlas Research Network (2014). Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature 507, 315–322.
Carpentier, A.-S., Riva, A., Tisseur, P., Didier, G., and He´naut, A. (2004). The
operons, a criterion to compare the reliability of transcriptome analysis
tools: ICA is more reliable than ANOVA, PLS and PCA. Comput. Biol.
Chem. 28, 3–10.
Cheng, W.-Y., Ou Yang, T.-H., and Anastassiou, D. (2013). Biomolecular
events in cancer revealed by attractor metagenes. PLoS Comput. Biol. 9,
e1002920.
Chiappetta, P., Roubaud, M.C., and Torre´sani, B. (2004). Blind source separa-
tion and the analysis of microarray data. J. Comput. Biol. 11, 1090–1109.
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E.R., Hoffman-Censits, J.,
Roth, B., Cheng, T., Tran, M., Lee, I.L., et al. (2014). Identification of distinct
basal and luminal subtypes of muscle-invasive bladder cancer with different
sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165.
Chung, C.H., Parker, J.S., Karaca, G., Wu, J., Funkhouser, W.K., Moore, D.,
Butterfoss, D., Xiang, D., Zanation, A., Yin, X., et al. (2004). Molecular classifi-
cation of head and neck squamous cell carcinomas using patterns of gene
expression. Cancer Cell 5, 489–500.
Cline, M.S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C.,
Christmas, R., Avila-Campilo, I., Creech,M., Gross, B., et al. (2007). Integration
of biological networks and gene expression data using Cytoscape. Nat. Pro-
toc. 2, 2366–2382.
Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast
cancer and hormone replacement therapy: collaborative reanalysis of data
from 51 epidemiological studies of 52,705 women with breast cancer and
108,411 women without breast cancer. Lancet 350, 1047–1059.
Damrauer, J.S., Hoadley, K.A., Chism, D.D., Fan, C., Tiganelli, C.J., Wobker,
S.E., Yeh, J.J., Milowsky, M.I., Iyer, G., Parker, J.S., and Kim, W.Y. (2014).
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast
cancer biology. Proc. Natl. Acad. Sci. USA 111, 3110–3115.
Di Palma, S., Simpson, R.H.W.,Marchio`, C., Ska´lova´, A., Ungari, M., Sandison,
A., Whitaker, S., Parry, S., and Reis-Filho, J.S. (2012). Salivary duct carci-
nomas can be classified into luminal androgen receptor-positive, HER2 and
basal-like phenotypes. Histopathology 61, 629–643.
Dyrskjøt, L., Kruhøffer, M., Thykjaer, T., Marcussen, N., Jensen, J.L., Møller,
K., and Ørntoft, T.F. (2004). Gene expression in the urinary bladder: a common
carcinoma in situ gene expression signature exists disregarding histopatho-
logical classification. Cancer Res. 64, 4040–4048.
Falcon, S., and Gentleman, R. (2007). Using GOstats to test gene lists for GO
term association. Bioinformatics 23, 257–258.
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M.
(2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int. J. Cancer 127, 2893–2917.
Frigyesi, A., Veerla, S., Lindgren, D., and Ho¨glund, M. (2006). Independent
component analysis reveals new and biologically significant structures in mi-
cro array data. BMC Bioinformatics 7, 290.
Himberg, J., Hyva¨rinen, A., and Esposito, F. (2004). Validating the independent
components of neuroimaging time series via clustering and visualization. Neu-
roimage 22, 1214–1222.
Hyva¨rinen, A. (1999). Fast and robust fixed-point algorithms for independent
component analysis. IEEE Trans. Neural Netw. 10, 626–634.
Jutten, C., and He´rault, J. (1991). Blind separation of sources, part I: An adap-
tive algorithm based on neuromimetic architecture. Signal Process. 24, 1–10.
Kim, W.J., Kim, E.J., Kim, S.K., Kim, Y.J., Ha, Y.S., Jeong, P., Kim, M.J., Yun,
S.J., Lee, K.M., Moon, S.K., et al. (2010). Predictive value of progression-
related gene classifier in primary non-muscle invasive bladder cancer. Mol.
Cancer 9, 3.
Kong, S.L., Li, G., Loh, S.L., Sung, W.K., and Liu, E.T. (2011). Cellular reprog-
ramming by the conjoint action of ERa, FOXA1, and GATA3 to a ligand-induc-
ible growth state. Mol. Syst. Biol. 7, 526.
Lee, S.-I., and Batzoglou, S. (2003). Application of independent component
analysis to microarrays. Genome Biol. 4, R76.hors
Liebermeister, W. (2002). Linear modes of gene expression determined by in-
dependent component analysis. Bioinformatics 18, 51–60.
Lin, D.W., Coleman, I.M., Hawley, S., Huang, C.Y., Dumpit, R., Gifford, D., Ke-
zele, P., Hung, H., Knudsen, B.S., Kristal, A.R., and Nelson, P.S. (2006). Influ-
ence of surgical manipulation on prostate gene expression: implications for
molecular correlates of treatment effects and disease prognosis. J. Clin. On-
col. 24, 3763–3770.
Rebouissou, S., Bernard-Pierrot, I., de Reynie`s, A., Lepage, M.L., Krucker, C.,
Chapeaublanc, E., He´rault, A., Kamoun, A., Caillault, A., Letouze´, E., et al.
(2014). EGFR as a potential therapeutic target for a subset of muscle-invasive
bladder cancers presenting a basal-like phenotype. Sci Transl Med 6,
244ra91.
Rouveirol, C., Stransky, N., Hupe´, P., Rosa, P.L., Viara, E., Barillot, E., and
Radvanyi, F. (2006). Computation of recurrent minimal genomic alterations
from array-CGH data. Bioinformatics 22, 849–856.
Sjo¨dahl, G., Lo¨vgren, K., Lauss, M., Patschan, O., Gudjonsson, S., Chebil, G.,
Aine, M., Eriksson, P., Ma˚nsson, W., Lindgren, D., et al. (2013). Toward a mo-
lecular pathologic classification of urothelial carcinoma. Am. J. Pathol. 183,
681–691.
Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie,
T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., et al. (2001). Gene expression
patterns of breast carcinomas distinguish tumor subclasses with clinical impli-
cations. Proc. Natl. Acad. Sci. USA 98, 10869–10874.
Spruck, C.H., 3rd, Ohneseit, P.F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N.,
Tsai, Y.C., Lerner, S.P., Schmu¨tte, C., Yang, A.S., Cote, R., et al. (1994). TwoCell Remolecular pathways to transitional cell carcinoma of the bladder. Cancer Res.
54, 784–788.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gil-
lette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Me-
sirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA
102, 15545–15550.
Teschendorff, A.E., Journe´e, M., Absil, P.A., Sepulchre, R., and Caldas, C.
(2007). Elucidating the altered transcriptional programs in breast cancer using
independent component analysis. PLoS Comput. Biol. 3, e161.
Turner, R.M., Kwok, C.S., Chen-Turner, C., Maduakor, C.A., Singh, S., and
Loke, Y.K. (2014). Thiazolidinediones and associated risk of bladder cancer:
a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 78, 258–273.
Vallot, C., Stransky, N., Bernard-Pierrot, I., He´rault, A., Zucman-Rossi, J., Cha-
peaublanc, E., Vordos, D., Laplanche, A., Benhamou, S., Lebret, T., et al.
(2011). A novel epigenetic phenotype associated with the most aggressive
pathway of bladder tumor progression. J. Natl. Cancer Inst. 103, 47–60.
Varley, C.L., Stahlschmidt, J., Lee, W.C., Holder, J., Diggle, C., Selby, P.J.,
Trejdosiewicz, L.K., and Southgate, J. (2004). Role of PPARgamma and
EGFR signalling in the urothelial terminal differentiation programme. J. Cell
Sci. 117, 2029–2036.
Wilkerson, M.D., Yin, X., Hoadley, K.A., Liu, Y., Hayward, M.C., Cabanski,
C.R., Muldrew, K., Miller, C.R., Randell, S.H., Socinski, M.A., et al. (2010).
Lung squamous cell carcinoma mRNA expression subtypes are reproducible,
clinically important, and correspond to normal cell types. Clin. Cancer Res. 16,
4864–4875.ports 9, 1235–1245, November 20, 2014 ª2014 The Authors 1245
